-
公开(公告)号：EP3177627A4
公开(公告)日：2018-03-07
申请号：EP15829416
申请日：2015-08-07
发明人： LI PENG , ZHENG HAILIN , ZHAO JUN , WENNOGLE LAWRENCE P
IPC分类号： C07D487/14 , A61K31/519 , A61K45/06 , A61P9/00
CPC分类号： A61K31/519 , A61K45/06 , C07D487/14 , A61K2300/00
摘要： The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
-
公开(公告)号：EP3125892A4
公开(公告)日：2017-12-27
申请号：EP15773031
申请日：2015-04-03
发明人： MATES SHARON , LI PENG , WENNOGLE LAWRENCE P , DAVIS ROBERT
IPC分类号： C07D471/16 , A61K31/4985 , A61P3/00 , A61P25/00 , A61P29/00 , C07B59/00
CPC分类号： C07D471/16 , A61K31/4985 , A61K45/06 , C07B59/002 , C07B2200/05
摘要： The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
-
公开(公告)号：EP3076967A4
公开(公告)日：2017-05-10
申请号：EP14867061
申请日：2014-12-03
发明人： VANOVER KIMBERLY , LI PENG , MATES SHARON , DAVIS ROBERT , WENNOGLE LAWRENCE P
IPC分类号： A61K31/437 , A61K9/52 , A61K31/4985 , A61K31/5383 , A61K45/06 , A61P25/18 , C07D241/36
CPC分类号： A61K31/5383 , A61K9/0019 , A61K9/0024 , A61K9/5153 , A61K31/4985 , A61K45/06 , A61K2300/00
摘要： The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
摘要翻译： 本公开提供了特定的取代的杂环稠合γ-咔啉化合物作为药物用于治疗精神病或精神分裂症残留症状的用途。 本公开还提供特定取代的杂环稠合γ-咔啉化合物的新型长效注射制剂和使用这种长效注射制剂来治疗精神病或精神分裂症的残留症状。
-
公开(公告)号：EP2968320A4
公开(公告)日：2016-10-05
申请号：EP14765123
申请日：2014-03-15
发明人： LI PENG , ZHANG QIANG , DAVIS ROBERT , WENNOGLE LAWRENCE P
IPC分类号： A61K31/4985 , A61K9/50
CPC分类号： C07D471/16 , A61K9/4825 , A61K9/4891 , A61K9/5031 , A61K31/4985 , A61K47/34 , A61K47/38 , C07D471/14
摘要： The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl -2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4 -fluorophenyl)-butan-1-one, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
-
公开(公告)号：EP2863918A4
公开(公告)日：2016-01-13
申请号：EP13806448
申请日：2013-06-21
发明人： LI PENG , WENNOGLE LAWRENCE P , DAVIS ROBERT , BUCKTON GRAHAM , HOOPER MARK
IPC分类号： A61K31/519 , A61P9/00 , A61P35/00 , C07D487/14
CPC分类号： C07D487/14 , C07B2200/13 , C07C55/02 , C07C57/15 , C07C309/04
摘要： The present invention relates to acid addition salt and salt crystals of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one, composition comprising the same and the method of making and using such salt and crystal.
-
公开(公告)号：EP2358204A4
公开(公告)日：2012-10-10
申请号：EP09830743
申请日：2009-12-07
发明人： LI PENG , WENNOGLE LAWRENCE P
IPC分类号： A61K31/522 , A61P25/00 , A61P27/06 , C07D487/14
CPC分类号： C07D487/14 , A61K31/165 , A61K31/519 , A61K31/5365 , A61K45/06
-
公开(公告)号：EP2367428A4
公开(公告)日：2012-06-06
申请号：EP09830742
申请日：2009-12-07
发明人： LI PENG , WENNOGLE LAWRENCE P , ZHAO JUN , ZENG HAILIN
IPC分类号： A01N43/90 , A61K31/00 , A61K31/5365 , C07D487/04
CPC分类号： C07D487/04 , A61K8/42 , A61K8/49 , A61K31/00 , A61K31/519 , A61K31/5365 , A61K45/06 , A61Q7/00
-
公开(公告)号：EP3125893A4
公开(公告)日：2017-09-20
申请号：EP15773589
申请日：2015-04-03
发明人： MATES SHARON , LI PENG , WENNOGLE LAWRENCE P , DAVIS ROBERT
IPC分类号： A61K31/4985 , A61K45/06 , A61P25/00 , C07B59/00 , C07D471/14 , C07D471/16
CPC分类号： C07D471/16 , A61K31/4985 , A61K45/06 , C07B59/002 , C07D471/14
摘要： The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
摘要翻译： 本发明涉及如本文所述的游离的，固体的，药学上可接受的盐和/或基本上纯的形式的特定取代的杂环稠合的γ-咔啉，其前药，其药物组合物，以及用于治疗涉及5-HT2A 受体，血清素转运蛋白（SERT）和/或涉及多巴胺D1 / D2受体信号传导系统的途径，和/或治疗残留症状。
-
公开(公告)号：EP2723173A4
公开(公告)日：2015-02-18
申请号：EP12802484
申请日：2012-06-22
发明人： LI PENG , PENG YOUYI , TOMESCH JOHN , WENNOGLE LAWRENCE P , ZHANG QIANG
IPC分类号： C07D401/12 , A61K31/454 , A61P25/28 , A61P25/34
CPC分类号： C07D401/12 , A61K31/41 , A61K31/415 , A61K31/454 , A61K31/4745 , A61K31/506 , A61K31/7068 , A61K33/24 , A61K45/06 , A61K2300/00
-
公开(公告)号：EP2590657A4
公开(公告)日：2014-02-12
申请号：EP11790276
申请日：2011-05-31
发明人： LI PENG , ZHENG HAILIN , ZHAO JUN , WENNOGLE LAWRENCE P
IPC分类号： A61K31/519 , A61P25/00 , C07D487/04
CPC分类号： C07D487/04 , A61K31/165 , A61K31/519 , A61K31/5575 , A61K45/06 , A61K2300/00
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.012 秒)
